Chiung-Hui Liu

Title: Innovations by Chiung-Hui Liu in Cancer Treatment

Introduction

Chiung-Hui Liu is an accomplished inventor based in Nantou County, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the preparation of supercritical extracts that have potential applications in oncology.

Latest Patents

Chiung-Hui Liu holds a patent for a preparation method of a supercritical extract derived from the dried stem of a specific material. This extract is obtained by pulverizing the material into particles and using supercritical carbon dioxide fluid for extraction. The active ingredient, subamolide A, has shown promise in inhibiting the growth of human urothelial carcinoma cell lines. Furthermore, subamolide A can synergistically enhance the effects of cisplatin (CDDP) or gemcitabine (Gem) in treating cancers related to the urinary system. This innovation positions subamolide A as a potential anticancer drug, either as a standalone treatment or in combination with other chemotherapeutic agents.

Career Highlights

Chiung-Hui Liu is affiliated with Kaohsiung Medical University, where he continues to advance his research in cancer therapies. His dedication to improving treatment options for patients is evident in his innovative approaches and methodologies.

Collaborations

Chiung-Hui Liu collaborates with esteemed colleagues, including Jih-Heng Li and A-Mei Huang, who contribute to his research efforts. Their combined expertise enhances the potential impact of their work in the medical field.

Conclusion

Chiung-Hui Liu's innovative research and patent in the field of cancer treatment highlight his commitment to advancing medical science. His work has the potential to significantly improve therapeutic options for patients suffering from urothelial carcinoma.